Chapter 4

Market Trajectory

The market Doximity sells into is not a rising tide. The company's own addressable-market estimate has stood at $18.5 billion since the 2021 IPO — unrevised through May 2026 — and it has captured only about 3.5% of it. The analog-to-digital advertising shift that once drove 40%-plus growth has cooled to mid-single-digit budget growth, and a fiscal-2028 revenue target of $1 billion management set in 2023 is now out of reach. Whether this stays a maturing niche or re-expands turns on AI-era clinical tools.

A market estimate frozen for five years

At its June 2021 IPO, Doximity sized its total addressable market at approximately $18.5 billion — $7.3 billion in U.S. pharmaceutical marketing to medical professionals, $6.9 billion in health-system marketing and staffing, and $4.3 billion in software telehealth [1]. Five years and five investor decks later, the number is unchanged: the May 2026 earnings presentation carries the same $7.3B / $6.9B / $4.3B breakdown and the same $18.5 billion total, under a slide still headed "Large & Growing Total Addressable Market" [2].

Sources: TAM from FY2026 investor deck [3]; penetration derived from FY2026 revenue of $644.9M [4]; FY2027 market-growth view from the Q4 FY2026 call [5].

Source: identical breakdown in the June 2021 prospectus [6] and the May 2026 investor deck [7].

A static market estimate carries two readings. On $644.9 million of FY2026 revenue [8], Doximity sits at roughly 3.5% of a $18.5 billion pool, which leaves a long nominal runway. But runway on a pool that has not grown in five years is a share-gain story, not a rising-tide one — and Doximity's own 10-K cautions that its market-opportunity estimates "may prove to be inaccurate" and that its business "may not grow at similar rates, or at all" even if the market does [9]. The size of the pond is not the question; how fast it is filling is.

The digital shift that already happened

Doximity's early growth rode one force: pharmaceutical and health-system budgets moving from print, in-person detailing and journals to digital channels. That shift is now largely behind the industry. Before the pandemic, management estimates pharma spent about 17% of its budget digitally; the pandemic drove digital budget growth of "roughly 30% to 40% a year"; and the post-pandemic period brought what the CFO called "a little bit of a digital detox," with budget growth settling into the mid-single digits [10]. The IPO thesis leaned on an IDC forecast that the U.S. healthcare and pharma industry would spend 38% of its advertising on digital by 2025 [11]; by 2026, industry trackers put healthcare and pharma digital at roughly 72% of the sector's media ad spend, overtaking linear TV. The transition the IPO priced as ahead of the company has mostly occurred.

Sources: pre-pandemic 17% per the Q2 FY2025 call [12]; the 38%-by-2025 IDC forecast from the IPO prospectus [13]; 2026 digital share per eMarketer industry data (not a filing).

What remains un-digitized is where the residual runway sits. Doximity's $7.3 billion pharma-marketing estimate deliberately excludes the roughly $16 billion pharma spends on physical drug samples and the direct-to-consumer budget, which the company says "may become addressable in the future if those dollars shift to physician marketing" [14]. Management's bull case is that professional promotion — details, meetings, samples — is "still very under indexed digitally," and that the medium-to-longer-term growth rate should exceed today's mid-single digits [15]. The counter is that broad healthcare advertising is already ~72% digital; the easy conversion has happened, and the remaining migration involves the stickiest analog budgets.

The growth rate has stepped down, not paused

Track the pharma HCP digital market-growth number management has cited and the deceleration is steady rather than a single cyclical dip. In August 2023 the company reported that digital pharma had grown at "half the low teens growth rate that we and e-marketer predicted," blamed a slowdown in pharma's shift to digital, and judged the market had "overcorrected this year to single-digit market growth" [16]. A year later it framed budget growth as mid-single digits [17]. By May 2025 it expected the market "to grow at roughly 5% to 7% again this year," prudently assuming the lower end [18]. By May 2026 it described near-term HCP digital pharma demand as "soft" with limited visibility, and guided its own FY2027 revenue to about 4% growth [19].

Source: midpoints of management's cited ranges across the FY2024–FY2027 earnings calls [20], [21], [22], [23].

The synchronized peer softness examined in Moat and Rivals argues part of this is cyclical — a pharma budget freeze on drug-pricing-policy uncertainty. But a step-down that has held for three consecutive years, against a market estimate that has not grown, is harder to read as purely cyclical. Management still insists mid-single-digit growth is not the long-run rate [24]; the burden of proof for a sunrise-sector view sits on that claim.

A billion-dollar target, receding

The clearest measure of how the industry narrative has moved is management's own outlook. On the August 2023 call, alongside a $460 million FY2024 revenue guide, the company said it continued "to see long-term growth rates north of 20% on our path to greater than $1 billion in revenue in fiscal 2028" [25]. Revenue reached $644.9 million in FY2026 [26], and the FY2027 guide of $664–676 million implies about 4% growth [27]. Reaching $1 billion the following year would require roughly 48% growth in FY2028 — against a mid-single-digit market. The target is no longer a plausible base case; the "north of 20%" long-term framing has not survived contact with the market.

Sources: revenue FY2022–FY2026 from the FY2026 10-K [28]; FY2027 guide midpoint and the former $1B FY2028 target from the FY2027 and FY2024 calls respectively [29], [30].

Where genuine growth still lives

Two parts of the sector are unambiguously fast-growing. Software telehealth — one of Doximity's three TAM buckets — is an independent market that trackers size in the $50–65 billion range and see compounding above 20% a year into the next decade. But Doximity's telehealth is a free workflow tool (Dialer) inside its physician offering, not a monetized growth engine, so the sector's fastest-growing slice is not where Doximity earns. The second is clinical AI. The FY2026 10-K now leads with "AI-powered tools specifically built for medicine" and a Clinical AI Suite spanning "patient communication to documentation to answering clinical questions" [31], and management says it is in "the early innings of realizing AI's full potential," with AI usage outgrowing overall workflow engagement [32], [33].

Clinical AI is the one credible route to re-expanding a frozen TAM — a genuinely new pool of clinical decision-support and point-of-care engagement that the $18.5 billion estimate does not capture. It is also the vector along which an AI-native rival is scaling into the same pharma budgets, as Moat and Rivals sets out. The same force that could enlarge the market could redistribute it. As of now the AI ramp shows up as a cost — the step-up in compute that pulls the FY2027 adjusted EBITDA margin to 49% from 55% — with the commercial return described as "potential ahead" rather than realized [34].

Reading the trajectory

On the evidence, Doximity's core market reads as a maturing niche with share-gain upside rather than a rising-tide sunrise sector. Its stated addressable market has not grown in five years; the digital-advertising shift that powered early hypergrowth is largely spent; the market-growth rate has stepped down for three straight years; and the $1 billion revenue target that embodied the old growth narrative has receded out of reach. The offsetting facts are real and worth weighting: penetration is only ~3.5%, so the company can grow well ahead of a flat market by taking share, as it did through FY2025 (Platform and Price); management argues the long-run rate is higher than today's; and telehealth and clinical AI are fast-growing adjacencies.

The read would change with evidence that the HCP digital pharma market re-accelerates above high-single digits, or that the Clinical AI Suite begins converting engagement into a materially larger monetizable pool. The most direct tell would be simple: an addressable-market number that finally moves off $18.5 billion. Until then, the industry backdrop supports a share-gains-in-a-flat-pool thesis, not the sunrise-sector premise a rising-tide case would need.